Director, MEG Lead Oncology, Medical Evidence Generation at Bristol-Myers Squibb

Princeton, New Jersey, United States

Apply Now

Not SpecifiedCompensation

Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Pharmaceuticals, BiotechnologyIndustries

Requirements

Advanced scientific degree (MD, PhD, or PharmD or the equivalent) required with extensive, relevant scientific, and/or clinical experience
At least 7 years of experience in pharmaceutical clinical development, Medical Affairs or relevant Commercial experience; previous customer-facing role experience highly desirable
Demonstrated ability to strategically analyze data generation opportunities with minimal supervision
Demonstrated ability to develop and sustain high-performing relationships with external thought leaders and internal matrix stakeholders
Adeptness at building credibility with external investigators and collaborative partners competently balancing business and scientific acumen complemented by strong leadership behaviors, authenticity, agility, and an enterprise mindset
Understanding of global healthcare systems and academic settings with a demonstrated ability to lead in ambiguous and changing healthcare/business environments
Exceptional communication and interpersonal skills to influence decision-making at all levels of the organization
In depth knowledge of overall project planning and project management of clinical trials
Proven ability to partner effectively with colleagues across multiple functions and at all levels of the enterprise

Responsibilities

Facilitate collaborative exchange between BMS and thought leaders in community practice and academia, including scientific dialogue and representing BMS as a trusted, inclusive, and innovative industry collaborator and partner of choice
Be accountable for delivering CRCs, ISRs, and MASTs from concept ideation to governance approval and throughout the study lifecycle
Act as point of contact for CRCs, ISRs, and MASTs within Therapeutic and Disease area teams
Design and drive strategies to accelerate the development of BMS’s clinical development pipeline leveraging external research platforms, technologies, and insights
Align with and advise senior functional and therapeutic area leaders on new external opportunities that will inform strategy and influence decisions in the creation/refinement of integrated evidence generation plans
Personally lead a limited number of high-visibility projects leveraging relevant disease subject matter expertise
Contribute to the evolution of MEG therapeutic area strategy and value proposition

Skills

Oncology

Medical Evidence Generation

Clinical Research Collaborations

Investigator-Sponsored Research

Medical Affairs Studies

Thought Leader Engagement

Study Lifecycle Management

Scientific Dialogue

Bristol-Myers Squibb

Develops and delivers biopharmaceutical medicines

About Bristol-Myers Squibb

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, focusing on areas like cancer, autoimmune diseases, and heart conditions. The company conducts extensive research and development to create new drugs, which are sold after receiving regulatory approval. BMS also produces generic drugs, offering affordable alternatives that meet the same quality standards as their branded counterparts. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, enhancing access to healthcare. The company's goal is to improve patient outcomes while maintaining a commitment to sustainability and corporate responsibility.

New York City, New YorkHeadquarters

1887Year Founded

$33,706.1MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

10,001+Employees

Benefits

Flexible Work Hours

Hybrid Work Options

Professional Development Budget

Risks

Increased competition in oncology from emerging biotech firms like ArsenalBio.

BMS's lawsuit over the 340B Drug Pricing Program may lead to regulatory challenges.

Rapid AI and digital tech evolution may pose integration challenges for BMS.

Differentiation

BMS focuses on innovative cancer treatments through collaborations like ArsenalBio for T cell therapies.

The company emphasizes digital health technologies, enhancing clinical trial management and patient engagement.

BMS offers both innovative and generic medicines, increasing affordable healthcare solutions.

Upsides

BMS's partnership with Medidata enhances clinical research processes and patient outcomes.

The collaboration with AI Proteins advances novel miniprotein-based therapeutics, expanding therapeutic modalities.

BMS's global license agreement with BioArctic expands its portfolio in neurodegenerative diseases.

Land your dream remote job 3x faster with AI

Try Jobo Free